Eisai loses DEA battle

Share this article:

Eisai's legal maneuver to pressure the DEA to schedule its FDA-approved epilepsy drug has failed. BioCentury reports that the District of Columbia's US Court of Appeals will not compel the Drug Enforcement Agency to put the seizure medication, Fycompa, on a schedule within a given time frame.

Without a designated schedule, Eisai cannot put the drug on the market, even though the patent life continues to wind down.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.